Of the 7223 incident invasive breast cancer cases, 5674 ER + (86.8%), 866 ER− (13.2%), 4379 PR + (67.4%), 2114 PR− (32.6%), 719 HER2 + (12.5%), and 5032 HER2− (87.5%) cases were identified (Table 2). This evidence concerns the gene PGR and invasive breast carcinoma.